Medexus Pharmaceuticals (TSX: MDP | OTCQX: MEDXF) held its virtual annual general meeting of shareholders on September 24, 2026, at which all seven director nominees were elected and PricewaterhouseCoopers LLP was reappointed as auditor. Shareholders also approved amendments to the company's equity incentive compensation plan. All proposals put to a vote received majority shareholder support, confirming continuity of board composition and governance structures heading into the next annual meeting.

Key Points

  • Medexus Pharmaceuticals (TSX: MDP | OTCQX: MEDXF) held its virtual 2026 annual meeting of shareholders on September 24, 2026.
  • All seven director nominees were elected; PricewaterhouseCoopers LLP was reappointed as auditor with 99.56% of votes cast in favour.
  • Shareholders approved equity incentive compensation plan amendments with 94.91% of votes in favour.
  • Investors may be watching whether board continuity and the updated equity compensation plan influence near-term executive retention and alignment strategies.

Director Election Results at Medexus 2026 Annual Meeting

All seven nominees listed in Medexus's management information circular dated August 10, 2026 were elected as directors through the next annual general meeting. Stephen Nelson received the highest level of support at 99.435% of votes cast in favour, while Ken d'Entremont, Harmony Garges, Michael Mueller, Nancy Phelan, and Menassie Taddese each received approximately 96.15% support. Benoit Gravel received the lowest level of support among elected directors at 79.163% in favour, with 20.837% of votes cast against, though this remained sufficient to secure election under the applicable voting threshold.

PricewaterhouseCoopers LLP Reappointed as Medexus Auditor

Shareholders voted overwhelmingly to reappoint PricewaterhouseCoopers LLP as the company's auditors, with 13,812,075 votes cast in favour, representing 99.560% of votes, and 61,000 votes withheld, representing 0.440%. The strong approval margin indicates broad shareholder confidence in the existing audit arrangement. The company did not disclose any changes to audit fees or engagement terms in the announcement.

Equity Incentive Compensation Plan Amendments Approved

Shareholders also voted in favour of resolutions amending Medexus's equity incentive compensation plan, with 10,906,889 votes cast for the amendments, representing 94.912%, and 584,632 votes against, representing 5.088%. The company did not provide specific details in the announcement regarding the nature or scope of the amendments approved. The equity plan changes may be of interest to investors monitoring executive compensation practices at the hematology and hemato-oncology focused pharmaceutical company.